Clearbridge Investments LLC Decreases Stock Holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Clearbridge Investments LLC trimmed its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) by 2.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 223,963 shares of the company’s stock after selling 5,709 shares during the quarter. Clearbridge Investments LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $5,586,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in FMS. Signaturefd LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 26.4% in the first quarter. Signaturefd LLC now owns 2,190 shares of the company’s stock valued at $74,000 after purchasing an additional 458 shares during the period. FDx Advisors Inc. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA during the first quarter worth $315,000. Envestnet Asset Management Inc. grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 94.5% during the first quarter. Envestnet Asset Management Inc. now owns 251,391 shares of the company’s stock worth $8,467,000 after purchasing an additional 122,169 shares in the last quarter. Advisor Group Holdings Inc. grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 30.6% during the first quarter. Advisor Group Holdings Inc. now owns 24,925 shares of the company’s stock worth $801,000 after purchasing an additional 5,842 shares in the last quarter. Finally, Sendero Wealth Management LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 5.9% during the first quarter. Sendero Wealth Management LLC now owns 12,768 shares of the company’s stock worth $430,000 after purchasing an additional 715 shares in the last quarter. Hedge funds and other institutional investors own 5.59% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

NYSE:FMS opened at $15.35 on Friday. The company has a current ratio of 1.34, a quick ratio of 0.96 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $9.00 billion, a price-to-earnings ratio of 10.89, a PEG ratio of 0.87 and a beta of 1.03. The firm’s fifty day simple moving average is $14.38 and its 200 day simple moving average is $20.15. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $12.78 and a twelve month high of $35.04.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Friday, July 29th. Berenberg Bank reduced their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €57.95 ($59.13) to €51.80 ($52.86) in a research report on Wednesday, October 26th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €24.00 ($24.49) to €22.00 ($22.45) and set a “sell” rating for the company in a research report on Thursday, November 3rd. Barclays reduced their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €40.00 ($40.82) to €36.00 ($36.73) and set an “equal weight” rating for the company in a research report on Friday, October 28th. Finally, Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research report on Monday, October 10th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $38.16.

About Fresenius Medical Care AG & Co. KGaA

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Recommended Stories

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.